Skip to main content

Advertisement

SpringerLink
Log in

Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

To evaluate major bleeding in cirrhosis with use of traditional anticoagulation or direct oral anticoagulants (DOACs), using a standardized definition. Anticoagulation in patients with cirrhosis is often a clinical conundrum for providers as the necessary balance between thrombotic and bleeding risk is complicated by end organ damage. Recent meta-analyses have sought to evaluate the safety and efficacy of direct oral anticoagulants in patients with liver disease. These recent analyses are limited by various bleeding definitions, broad inclusion criteria, and few indications for anticoagulation. We sought to conduct a meta-analysis using a validated definition for major bleeding and compare rates between traditional anticoagulation and DOACs in patients with cirrhosis. Articles were eligible for inclusion if the international society on thrombosis and hemostasis (ISTH) definition of a major bleed was the primary safety outcome. Additionally, only articles including patients with cirrhosis and receiving treatment with anticoagulation for an indication for stroke prevention or venous thromboembolism were eligible. Eligible articles needed a DOAC comparator group against traditional anticoagulant medication. Seven studies met inclusion criteria and compiled data for 683 patients in the meta-analysis. Pooled trial analysis demonstrated no statistically significant difference in the primary outcome of ISTH major bleeding (OR 0.55, 95%CI 0.28–1.07, I2 0%). Individual secondary outcomes of all bleeding, intracerebral hemorrhage, or gastrointestinal bleeding also demonstrated no significant difference between DOACs and traditional anticoagulation. Use of DOACs in patients with mild to moderate cirrhosis carries similar risk to use of traditional anticoagulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Julia S, James U (2017) Direct oral anticoagulants: a quick guide. Eur Cardiol 12(1):40–45. https://doi.org/10.15420/ecr.2017:11:2

    Article  PubMed  PubMed Central  Google Scholar 

  2. Lee LH (2016) DOACs—Advances and limitations in real world. Thromb J 14(1):17. https://doi.org/10.1186/s12959-016-0111-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Chan Y-H, Lee H-F, See L-C, Tu H-T, Chao T-F, Yeh Y-H et al (2019) Effectiveness and safety of four direct oral anticoagulants in Asian patients With nonvalvular atrial fibrillation. Chest 156(3):529–543. https://doi.org/10.1016/j.chest.2019.04.108

    Article  PubMed  Google Scholar 

  4. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315–352. https://doi.org/10.1016/j.chest.2015.11.026

    Article  PubMed  Google Scholar 

  5. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC et al (2019) AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol 74(1):104–132. https://doi.org/10.1016/j.jacc.2019.01.011

    Article  PubMed  Google Scholar 

  6. Tripodi A, Mannucci PM (2011) The coagulopathy of chronic liver disease. N Engl J Med 365(2):147–156. https://doi.org/10.1056/NEJMra1011170

    Article  CAS  PubMed  Google Scholar 

  7. Kujovich JL (2015) Coagulopathy in liver disease: a balancing act. Hematology 2015(1):243–249. https://doi.org/10.1182/asheducation-2015.1.243

    Article  PubMed  Google Scholar 

  8. Li B, Zhang C, Zhan Y-T (2018) Nonalcoholic fatty liver disease cirrhosis: a review of its epidemiology, risk factors, clinical presentation, diagnosis, management, and prognosis. Can J Gastroenterol Hepatol 2018:2784537. https://doi.org/10.1155/2018/2784537

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ballestri S, Capitelli M, Fontana MC, Arioli D, Romagnoli E, Graziosi C et al (2020) Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review. Adv Ther 37(5):1910–1932. https://doi.org/10.1007/s12325-020-01307-z

    Article  PubMed  PubMed Central  Google Scholar 

  10. De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B et al (2017) Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int 37(5):694–699. https://doi.org/10.1111/liv.13285

    Article  CAS  PubMed  Google Scholar 

  11. Intagliata NM, Maitland H, Northup PG, Caldwell SH (2015) Treating thrombosis in cirrhosis patients with new oral agents: Ready or not? Hepatology 61(2):738–739. https://doi.org/10.1002/hep.27225

    Article  CAS  PubMed  Google Scholar 

  12. Kunk PR, Collins H, Palkimas S, Intagliata NM, Maitland HS (2016) Direct oral anticoagulants in patients with cirrhosis appear safe and effective. Blood 128(22):3827. https://doi.org/10.1182/blood.V128.22.3827.3827

    Article  Google Scholar 

  13. Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Shinohara F, Nakamura Y et al (2018) Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res 48(1):51–58. https://doi.org/10.1111/hepr.12895

    Article  CAS  PubMed  Google Scholar 

  14. Pastori D, Lip GYH, Farcomeni A, Del Sole F, Sciacqua A, Perticone F et al (2018) Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Int J Cardiol 264:58–63. https://doi.org/10.1016/j.ijcard.2018.01.097

    Article  PubMed  Google Scholar 

  15. Chokesuwattanaskul R, Thongprayoon C, Bathini T, Torres-Ortiz A, O’Corragain OA, Watthanasuntorn K et al (2019) Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: A systematic review and meta-analysis. Dig Liver Dis 51(4):489–495. https://doi.org/10.1016/j.dld.2018.12.001

    Article  PubMed  Google Scholar 

  16. Lapumnuaypol K, DiMaria C, Chiasakul T (2019) Safety of direct oral anticoagulants in patients with cirrhosis: a systematic review and meta-analysis. QJM: Int J Med 112(8):605–610. https://doi.org/10.1093/qjmed/hcz127

    Article  CAS  Google Scholar 

  17. Huang ZC, Li CQ, Liu XY, Cao ZC, Jia HY, Dong Y et al (2020) Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review. Cardiovasc Drugs Ther. https://doi.org/10.1007/s10557-020-07065-y

    Article  PubMed  Google Scholar 

  18. Menichelli D, Ronca V, Di Rocco A, Pignatelli P, Marco Podda G (2020) Direct oral anticoagulants and advanced liver disease: a systematic review and meta-analysis. Eur J Clin Invest 51(3):e13397. https://doi.org/10.1111/eci.13397

    Article  PubMed  Google Scholar 

  19. Violi F, Vestri A, Menichelli D, Di Rocco A, Pastori D, Pignatelli P (2020) Direct oral anticoagulants in patients with atrial fibrillation and advanced liver disease: an exploratory meta-analysis. Hepatol Commun 4(7):1034–1040. https://doi.org/10.1002/hep4.1513

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Fu Y, Zhu W, Zhou Y, Chen H, Yan L, He W (2020) Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review. Am J Cardiovasc Drugs 20(2):139–147. https://doi.org/10.1007/s40256-019-00369-x

    Article  CAS  PubMed  Google Scholar 

  21. Davis KA, Joseph J, Nisly SA (2020) Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes. J Thromb Thrombolysis 50(2):457–461. https://doi.org/10.1007/s11239-019-02035-0

    Article  PubMed  Google Scholar 

  22. Goriacko P, Veltri KT (2018) Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation. Eur J Haematol 100(5):488–493. https://doi.org/10.1111/ejh.13045

    Article  CAS  PubMed  Google Scholar 

  23. Hanafy AS, Abd-Elsalam S, Dawoud MM (2019) Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vasc Pharmacol 113:86–91. https://doi.org/10.1016/j.vph.2018.05.002

    Article  CAS  Google Scholar 

  24. Hum J, Shatzel JJ, Jou JH, Deloughery TG (2017) The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol 98(4):393–397. https://doi.org/10.1111/ejh.12844

    Article  CAS  PubMed  Google Scholar 

  25. Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG et al (2016) Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci 61(6):1721–1727. https://doi.org/10.1007/s10620-015-4012-2

    Article  CAS  PubMed  Google Scholar 

  26. Jones K, Pham C, Aguilar C, Sheth S (2020) Retrospective review on the safety and efficacy of direct oral anticoagulants compared with warfarin in patients with cirrhosis. Fed Pract 37(10):479–485. https://doi.org/10.12788/fp.0058

    Article  PubMed  PubMed Central  Google Scholar 

  27. Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Mascarenhas J, Schiano T (2020) Safety, efficacy, and long-term outcomes of anticoagulation in cirrhotic portal vein thrombosis. Dig Dis Sci. https://doi.org/10.1007/s10620-020-06695-4

    Article  PubMed  Google Scholar 

  28. Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694. https://doi.org/10.1111/j.1538-7836.2005.01204.x

    Article  CAS  PubMed  Google Scholar 

  29. Laporte S, Chapelle C, Bertoletti L, Ollier E, Zufferey P, Lega J-C et al (2017) Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta-analysis of randomized controlled trials. J Thromb Haemost 15(8):1547–1558. https://doi.org/10.1111/jth.13740

    Article  CAS  PubMed  Google Scholar 

  30. Lee H-F, Chan Y-H, Chang S-H, Tu H-T, Chen S-W, Yeh Y-H et al (2019) Effectiveness and safety of non-vitamin K antagonist oral anticoagulant and warfarin in cirrhotic patients with nonvalvular atrial fibrillation. J Am Heart Assoc 8(5):e011112. https://doi.org/10.1161/JAHA.118.011112

    Article  PubMed  PubMed Central  Google Scholar 

  31. Lee S-R, Lee H-J, Choi E-K, Han K-D, Jung J-H, Cha M-J et al (2019) Direct oral anticoagulants in patients with atrial fibrillation and liver disease. J Am Coll Cardiol 73(25):3295–3308. https://doi.org/10.1016/j.jacc.2019.04.052

    Article  CAS  PubMed  Google Scholar 

  32. Qamar A, Antman EM, Ruff CT, Nordio F, Murphy SA, Grip LT et al (2019) Edoxaban versus warfarin in patients with atrial fibrillation and history of liver disease. J Am Coll Cardiol 74(2):179–189. https://doi.org/10.1016/j.jacc.2019.04.061

    Article  CAS  PubMed  Google Scholar 

  33. Wang C-L, Wu VC-C, Kuo C-F, Chu P-H, Tseng H-J, Wen M-S et al (2018) Efficacy and safety of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with impaired liver function: a retrospective cohort study. J Am Heart Assoc 7(15):e009263. https://doi.org/10.1161/JAHA.118.009263

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ai M-h, Dong W-g, Tan X-p, Xu L, Xu C, Zhang Q et al (2020) Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 32(10):1395–1400. https://doi.org/10.1097/meg.0000000000001846

    Article  CAS  PubMed  Google Scholar 

  35. Serper M, Weinberg EM, Cohen JB, Reese PP, Taddei TH, Kaplan DE (2020) Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation. Hepatology. https://doi.org/10.1002/hep.31264

    Article  PubMed  Google Scholar 

Download references

Funding

The authors report no funding for this research.

Author information

Authors and Affiliations

  1. School of Pharmacy, Wingate University, Wingate, USA

    Sarah A. Nisly

  2. Department of Pharmacy, Wake Forest Baptist Health, 1 Medical Center Blvd, Winston-Salem, NC, 27157, USA

    Sarah A. Nisly, Alexandra E. Mihm, Kyle A. Davis & Janine Tillett

  3. Wake Forest School of Medicine, 1 Medical Center Blvd, Winston-Salem, NC, 27157, USA

    Chris Gillette

Authors
  1. Sarah A. Nisly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexandra E. Mihm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chris Gillette
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kyle A. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Janine Tillett
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JT performed the literature search. KD and AM completed the literature screening. SN and AM performed data extraction. CG performed the statistical analysis. All authors contributed to manuscript drafts, revisions, and final edits.

Corresponding author

Correspondence to Sarah A. Nisly.

Ethics declarations

Conflicts of interest

The authors report no conflicts of interest.

Ethical approval

IRB approval was not necessary or gained for this meta-analysis.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 14 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nisly, S.A., Mihm, A.E., Gillette, C. et al. Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis. J Thromb Thrombolysis 52, 817–827 (2021). https://doi.org/10.1007/s11239-021-02424-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-021-02424-4

Keywords

Search

Navigation